Fascinating tidbits: not suggesting pharmacological effects but perhaps indicating slower, milder effects? Each reference is open access.
"The aggregation of α-synuclein is one on the key pathogenic events in Parkinson's disease." (4)
"A variety of flavonoids inhibited alpha-synuclein fibrillation, and
most of the strong inhibitory flavonoids were also found to disaggregate
preformed fibrils." (1) "Table S1 in Supplementary Materials....
lists the name, synonym, and structure of the flavonoid from each
"To develop disease modifying therapies for α-synucleinopathies, we
examined effects of phenolic compounds on α-synuclein (αS)
oligomerization. Phenolic compounds, especially Myricetin (Myr) and
Rosmarinic acid (RA), inhibited αS oligomerization and secondary
structure conversion. Myr and RA ameliorated αS synaptic toxicity on the
experiment of long-term potentiation. Our results suggest that Myr and
RA prevent αS aggregation process and reduce the neurotoxicity of αS
"Piceatannol inhibited the formation of α synuclein fibrils and was able
to destabilize preformed filaments. It seems to induce the formation of
small soluble complexes protecting membranes against
α-synuclein-induced damage. Finally, piceatannol protected cells against
α-synuclein-induced toxicity." (4)
"Red wine is particularly rich in specific polyphenolic compounds that
appear to affect the biological processes of AD and PD, such as
quercetin, myricetin, catechins, tannins, anthocyanidins, resveratrol,
and ferulic acid. Indeed, there is now a consistent body of in vitro and
in vivo data on the neuroprotective effects of red wine polyphenols
(RWP) showing that they do not merely possess antioxidant properties,
but may additionally act upon, in a multi-target manner, the underlying
key mechanisms featuring in both AD and PD. Furthermore, it is important
that bioavailability issues are addressed in order for neuroprotection
to be relevant in a clinical study scenario. This review summarizes the
current knowledge about the major classes of RWP and places into
perspective their potential to be considered as nutraceuticals to target
neuropathology in AD and PD." (5)
1. Effects of Various Flavonoids on the α-Synuclein Fibrillation Process.
Meng X, Munishkina LA, Fink AL, Uversky VN.
Parkinsons Dis. 2010 Jan 28;2010:650794.
2. Table S1
3. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
Takahashi R, Ono K, Takamura Y, Mizuguchi M, Ikeda T, Nishijo H, Yamada M.
J Neurochem. 2015 Sep;134(5):943-55.
4. Piceatannol and Other Wine Stilbenes: A Pool of Inhibitors against α-Synuclein Aggregation and Cytotoxicity.
Temsamani H, Krisa S, Decossas-Mendoza M, Lambert O, Mérillon JM, Richard T.
Nutrients. 2016 Jun 15;8(6). pii: E367.
5. Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's Disease.
Caruana M, Cauchi R, Vassallo N.
Front Nutr. 2016 Aug 12;3:31.